These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 33646464)

  • 1. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
    Aoki M; Iwasa S; Boku N
    Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
    Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
    Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
    Mishima S; Shitara K
    Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
    [No Abstract]   [Full Text] [Related]  

  • 4. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
    N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
    Ishii T; Shitara K
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1193-1201. PubMed ID: 34543577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
    Nakajima S; Mimura K; Matsumoto T; Thar Min AK; Ito M; Nakano H; Neupane P; Kanke Y; Okayama H; Saito M; Momma T; Watanabe Y; Hanayama H; Hayase S; Saze Z; Kono K
    Sci Rep; 2021 Aug; 11(1):16891. PubMed ID: 34413454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
    Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
    Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
    Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
    Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Sakamoto Y; Nishina T; Inaki K; Kuwahara Y; Wada N; Suto F; Arita T; Sugihara M; Tsuchihashi Z; Saito K; Kojima A; Yamaguchi K
    Nat Med; 2024 Jul; 30(7):1933-1942. PubMed ID: 38745009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab deruxtecan in breast cancer.
    Martín M; Pandiella A; Vargas-Castrillón E; Díaz-Rodríguez E; Iglesias-Hernangómez T; Martínez Cano C; Fernández-Cuesta I; Winkow E; Perelló MF
    Crit Rev Oncol Hematol; 2024 Jun; 198():104355. PubMed ID: 38621469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
    Ali A; Graff SL
    Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.
    Kang C
    Target Oncol; 2023 Nov; 18(6):981-989. PubMed ID: 37787931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer.
    Kotani D; Shitara K
    Ther Adv Med Oncol; 2021; 13():1758835920986518. PubMed ID: 33473250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
    Shitara K
    Future Oncol; 2024 Jan; 20(2):59-70. PubMed ID: 37916503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
    Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
    BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.